Hypertension induced by vascular endothelial growth factor signaling pathway inhibition: mechanisms and potential use as a biomarker - Wikidata - awgldk - TriplyDB

Hypertension induced by vascular endothelial growth factor signaling pathway inhibition: mechanisms and potential use as a biomarker

Hypertension induced by vascular endothelial growth factor signaling pathway inhibition: mechanisms and potential use as a biomarker

http://www.wikidata.org/entity/Q24595773

about

Selective use of sorafenib in the treatment of thyroid cancer The Role of CC-Chemokines in the Regulation of Angiogenesis Putative Key Role of Inositol Messengers in Endothelial Cells in Preeclampsia First-in-human phase I study of PRS-050 (Angiocal), an Anticalin targeting and antagonizing VEGF-A, in patients with advanced solid tumors A network pharmacology study of Chinese medicine QiShenYiQi to reveal its underlying multi-compound, multi-target, multi-pathway mode of action Renal thrombotic microangiopathy and podocytopathy associated with the use of carfilzomib in a patient with multiple myeloma.Hypoxia-induced endothelial progenitor cell function is blunted in angiotensinogen knockout mice.Cediranib in patients with malignant mesothelioma: a phase II trial of the University of Chicago Phase II Consortium.Hypertension among patients with renal cell carcinoma receiving axitinib or sorafenib: analysis from the randomized phase III AXIS trial Nephrotoxicity of recent anti-cancer agents.Cardiotoxicity of molecularly targeted agents Regorafenib induces rapid and reversible changes in plasma nitric oxide and endothelin-1 Treatment of experimental human breast cancer and lung cancer brain metastases in mice by macitentan, a dual antagonist of endothelin receptors, combined with paclitaxel.Cardiovascular complications associated with novel angiogenesis inhibitors: emerging evidence and evolving perspectives.Bevacizumab use and risk of cardiovascular adverse events among elderly patients with colorectal cancer receiving chemotherapy: a population-based study.Control of hypertension in the critically ill: a pathophysiological approach.Mechanisms of Cardiotoxicity of Cancer Chemotherapeutic Agents: Cardiomyopathy and Beyond.Outcomes in Patients With Metastatic Renal Cell Carcinoma Who Develop Everolimus-Related Hyperglycemia and Hypercholesterolemia: Combined Subgroup Analyses of the RECORD-1 and REACT Trials.Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with pazopanib after disease progression with other targeted therapies Hydrogen sulfide attenuates sFlt1-induced hypertension and renal damage by upregulating vascular endothelial growth factor Progress and contrasts of the development of tivozanib for therapy of kidney cancer.Cardiovascular toxicity of tyrosine kinase inhibitors.Cardiovascular safety of tyrosine kinase inhibitors: with a special focus on cardiac repolarisation (QT interval).Cardiovascular safety and hemodynamic considerations in oncology drug development - webinar highlights October 10th 2012.Vascular endothelial growth factor inhibitor-induced hypertension: from pathophysiology to prevention and treatment based on long-acting nitric oxide donors.Anti-angiogenic agent ramucirumab: meaningful or marginal?The contribution of VEGF signalling to fostamatinib-induced blood pressure elevation.Long-term toxicity of bevacizumab therapy in neurofibromatosis 2 patients.Hypertension and VEGF (Vascular Endothelial Growth Factor) Receptor Tyrosine Kinase Inhibition: Effects on Renal Function.In vitro pharmacological profiling of R406 identifies molecular targets underlying the clinical effects of fostamatinib.Personalized Therapy Against Preeclampsia by Replenishing Placental Protein 13 (PP13) Targeted to Patients With Impaired PP13 Molecule or Function.Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumor after failure with imatinib and sunitinib treatment: A meta-analysis.Angiogenesis and Anti-Angiogenic Therapy in Gastric Cancer.Quantifying the relationship between inhibition of VEGFR-2, drug-induced blood pressure elevation and hypertension.Icrucumab, a fully human monoclonal antibody against the vascular endothelial growth factor receptor-1, in the treatment of patients with advanced solid malignancies: a Phase 1 study.Vascular endothelial growth factor (VEGF)-634G/C polymorphism was associated with severe pre-eclampsia and lower serum VEGF level.Mechanisms of VEGF (Vascular Endothelial Growth Factor) Inhibitor-Associated Hypertension and Vascular Disease.Bevacizumab-induced hypertension: Clinical presentation and molecular understanding.Cardiovascular toxic effects of targeted cancer therapy.

P2860

Q26752891-C6AD6299-37EF-4F36-8226-F58B2FB0DB5B Q28077024-70E01180-500D-4E63-956F-5C718CBA590F Q28080015-AA7C5BAB-3A02-44D3-85B8-093A96BF11F0 Q28537681-48919C3F-362B-45D3-986B-D64302CC2BAA Q28538646-6D8ABCD6-1531-4EA8-8DD2-22A39278BFCD Q33417910-61410DBC-7497-4542-A7BF-0B1F6EFE5C44 Q33861718-12D36B28-61B0-48EF-8626-48CD86A17E3E Q35057364-C65901E9-27B3-40A0-9722-90647C35F485 Q35187848-EA4C2A89-7204-412B-B33F-364669FCC2D1 Q35310741-1D3AA592-F0FE-4EFA-8C14-145C87E4A956 Q35878459-411F126F-4250-4E35-BA84-BC9BB7305CC3 Q36627125-BCC3DF5F-6EC4-4914-A7B1-F91346953839 Q36705944-9FA09263-2C46-4E06-ADA6-CD97979CB630 Q36751861-A6314248-8695-4C65-94B9-39313C32D54B Q36862836-9D14691E-B15C-4E7E-9148-EE898CCB097B Q36992884-A7B43A95-D7E4-42FD-86BE-0147236575BB Q37038711-B858343F-4EFA-4536-A1CF-048BBC883FD6 Q37337031-3ECA6795-E2BC-4BB6-9147-0CB35351A9EB Q37438970-9710529B-DDB9-4D05-A0C7-8ABCE972B87A Q37670305-F6B4F83E-FF47-4F97-8B0A-80EADFA0164E Q37958038-6689F7B0-B408-4364-ACAC-F067F38CB78D Q38096429-34DAE68E-3476-47A1-A6E9-3EE5389ED026 Q38101883-9D98CC25-621A-49EC-9F4A-94A6B1DD2EEB Q38104812-621908CD-3E8B-4C41-B214-ED24B2863A3D Q38156262-928D480E-A0E4-4304-B987-87F46DC540E2 Q38194159-9E85D51A-0987-416A-A0B8-68ED3959E82F Q38925714-48471A25-728B-4407-ACE2-2C80D6415F44 Q39214055-7AAF92DD-9C57-40DB-9011-275106174177 Q40109938-8D490ECF-5278-429F-8BFE-01D220F338FF Q41773428-C0E4BFF0-9FC1-49B8-B756-1F3E1FC6B875 Q42373442-7063D518-BC80-46C9-8305-8817A7E44204 Q47105124-1758E062-1CAE-4BF3-80CC-E354C6A4C8B5 Q47218543-9129F441-FBC3-48EF-B023-040F0B30B42A Q47434764-991A6BB2-F75C-4CD9-AE74-332D778E3C3C Q47888326-8DFFA9A4-96DD-41B2-8E06-0551A31978BE Q48117226-189D21B4-40D7-4427-BA92-7310251CF60A Q49568718-F197D998-A7A9-4D6C-9048-A48EEB708FAC Q50204127-5F0EAF98-97FB-454F-A8E2-883ECFEA7521 Q53276936-9B456C21-8C34-490C-A4BD-4E8550596007

P2860

Hypertension induced by vascular endothelial growth factor signaling pathway inhibition: mechanisms and potential use as a biomarker

http://www.wikidata.org/entity/Q24595773

description

2010 nî lūn-bûn

@nan

2010 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Hypertension induced by vascul ...... d potential use as a biomarker

@ast

Hypertension induced by vascul ...... d potential use as a biomarker

@en

Hypertension induced by vascul ...... d potential use as a biomarker

@nl

type

label

Hypertension induced by vascul ...... d potential use as a biomarker

@ast

Hypertension induced by vascul ...... d potential use as a biomarker

@en

Hypertension induced by vascul ...... d potential use as a biomarker

@nl

prefLabel

Hypertension induced by vascul ...... d potential use as a biomarker

@ast

Hypertension induced by vascul ...... d potential use as a biomarker

@en

Hypertension induced by vascul ...... d potential use as a biomarker

@nl

P1433

Q24595773-6EFEDAEB-D384-4489-8F26-16A01742BCF7

P1476

Q24595773-7E2A64AD-C11E-413D-8202-B7EB8895CB0F

P2093

Q24595773-33B93A84-9F43-451F-A2CE-F060EBDC4867

Q24595773-378318A0-14CA-4DA2-BEC5-0A885DAD6E78

Q24595773-86FF9CED-CE63-4143-8C80-84326767FB6C

P2860

Q24595773-051951BA-FA1D-4B9D-B30E-A141D1498D2D

Q24595773-0B5F5E73-40BE-4F8F-AB17-40C432DCCF16

Q24595773-10A7F455-1BDA-406A-9376-3B0FF35D5838

Q24595773-1C59B532-43DF-4FB6-ADAC-80F9BA3BC01A

Q24595773-20FA04D1-ADB3-4AF9-9F81-9529382918A8

Q24595773-246660F8-9BAE-4FE2-B450-CD402569264B

Q24595773-26B7BFB7-8FD3-442D-A02B-957876CA488E

Q24595773-26B90DF0-C45F-44C9-A4CF-491319B7757A

Q24595773-2A012D1F-FB14-4A92-8627-A119B319A02B

Q24595773-2D1D402C-F4B0-4A2B-8006-C58F90556D20

P304

Q24595773-671116CC-E737-4EFF-B4D5-6D5332970462

P31

Q24595773-9e6ee217-8a90-4f2d-9908-8c964a9447d3

Q24595773-AD7B5141-1338-4F9F-985B-A0A4F48EB0EE

P3181

Q24595773-65F2DB36-EEE4-41CD-8D85-72F250D6EBC0

P356

Q24595773-CDF90BC1-6DF5-446E-A329-3AD25A748572

P407

Q24595773-91FC2F35-BB2D-43EC-8DA7-82A97802EDDD

P433

Q24595773-DEA7E772-4F5D-41EA-8480-31ECEE531B37

P478

Q24595773-BA2A9A20-0104-45A4-8484-3B65721EF277

P50

Q24595773-6E71941B-6613-4360-AE09-80F87A02F3B6

P577

Q24595773-BE08D6FF-C414-4E92-8A89-3CFA194E2806

P5875

Q24595773-45594EF7-918B-426A-B17F-848FBE36AC71

P698

Q24595773-76394F3F-BBE7-46F7-9DE1-7FCDF9A73016

P921

Q24595773-76840F3E-BA5A-4559-989B-DE91B8376FFC

Q24595773-DF3E5821-E8B7-448F-AFE1-9283F85ED2B9

P932

Q24595773-531AAEB7-D855-4E72-AE32-11DDB65C5CE8

P3181

P356

J.SEMNEPHROL.2010.09.007

P1433

Seminars in Nephrology

P1476

Hypertension induced by vascul ...... d potential use as a biomarker

@en

P2093

Benjamin D Humphreys

http://www.w3.org/2001/XMLSchema#string

Eliyahu V Khankin

http://www.w3.org/2001/XMLSchema#string

Emily S Robinson

http://www.w3.org/2001/XMLSchema#string

P2860

Regulation of endothelium-derived nitric oxide production by the protein kinase Akt

Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment

Tumor angiogenesis: therapeutic implications

Macrophages regulate salt-dependent volume and blood pressure by a vascular endothelial growth factor-C-dependent buffering mechanism

Role of endothelin in mediating soluble fms-like tyrosine kinase 1-induced hypertension in pregnant rats

Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene

Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele

Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia

Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid

Hypertension and rarefaction during treatment with telatinib, a small molecule angiogenesis inhibitor.

P304

591-601

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

3406901

http://www.w3.org/2001/XMLSchema#string

P356

10.1016/J.SEMNEPHROL.2010.09.007

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

30

http://www.w3.org/2001/XMLSchema#string

P50

S Ananth Karumanchi

P577

2010-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49672060

http://www.w3.org/2001/XMLSchema#string

P698

21146124

http://www.w3.org/2001/XMLSchema#string

P921

arterial hypertension

P932

3058726

http://www.w3.org/2001/XMLSchema#string